Genscript Biotech Gestione
Criteri Gestione verificati 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Sherry Shao
Amministratore delegato
US$2.8m
Compenso totale
| Percentuale dello stipendio del CEO | 14.43% |
| Mandato del CEO | 5yrs |
| Proprietà del CEO | 0.07% |
| Durata media del management | 4.3yrs |
| Durata media del Consiglio di amministrazione | 3.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jun 23
1548: New Expression Platform Will Support Future Cell Therapy Upside
Analysts have made a small adjustment to their price target for Genscript Biotech to HK$17.68. This reflects updated views on the company’s fair value, discount rate, revenue growth, profit margin and future P/E assumptions.Aggiornamento narrativa • Jun 06
1548: European mRNA Buildout And Cell Therapy Data Will Support Future Upside
Analysts have made a very small upward adjustment to Genscript Biotech's fair value estimate, moving the target from about HK$17.67 to roughly HK$17.67. They refreshed assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect current views on the business.Aggiornamento narrativa • May 12
1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).Aggiornamento narrativa • Apr 24
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).Aggiornamento narrativa • Apr 10
1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Nuova narrativa • Mar 31
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Mar 25
1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).Aggiornamento narrativa • Mar 10
1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.Aggiornamento narrativa • Feb 23
1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.Aggiornamento narrativa • Feb 09
1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Articolo di analisi • Nov 03
Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...Articolo di analisi • Oct 10
Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...Articolo di analisi • Sep 18
We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...Articolo di analisi • Sep 08
Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aggiornamento narrativa • Aug 21
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Articolo di analisi • Jul 29
Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues
Genscript Biotech Corporation ( HKG:1548 ) shares have continued their recent momentum with a 28% gain in the last...Nuova narrativa • Jul 17
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Dec 31 2025 | US$3m | US$405k | -US$533m |
| Sep 30 2025 | n/a | n/a | -US$264m |
| Jun 30 2025 | n/a | n/a | US$5m |
| Mar 31 2025 | n/a | n/a | -US$31m |
| Dec 31 2024 | US$4m | US$352k | -US$67m |
| Jun 30 2024 | n/a | n/a | US$419m |
| Mar 31 2024 | n/a | n/a | US$421m |
| Dec 31 2023 | US$2m | US$353k | US$423m |
Compensazione vs Mercato: La retribuzione totale di Sherry ($USD 2.81M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 1.01M ).
Compensazione vs guadagni: La retribuzione di Sherry è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Sherry Shao (46 yo)
5yrs
Mandato
US$2,807,000
Compensazione
Ms. Weihui Shao, also known as Sherry, is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined t...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 10.9yrs | US$525.00k | 0.016% HK$ 6.2m | |
| CEO & COO | 5yrs | US$2.81m | 0.073% HK$ 27.6m | |
| Co-Founder | 24.5yrs | US$803.00k | 0.040% HK$ 15.1m | |
| Co-Founder & Executive Director | 3.6yrs | US$645.00k | Nessun dato | |
| Chief Strategy Officer & Executive Director | 5.7yrs | US$595.00k | 0.049% HK$ 18.7m | |
| Chief Financial Officer | 1.2yrs | Nessun dato | Nessun dato | |
| General Counsel & Chief Compliance Officer | no data | Nessun dato | Nessun dato | |
| Head of Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief Marketing Officer for GenScript Life Science Group | 1.7yrs | Nessun dato | Nessun dato | |
| Head of Global Diversity | no data | Nessun dato | Nessun dato | |
| Head of Sustainability | no data | Nessun dato | Nessun dato | |
| President of GenScript Life Science Group | no data | Nessun dato | Nessun dato |
4.3yrs
Durata media
58yo
Età media
Gestione esperta: Il team dirigenziale di 1548 è considerato esperto (durata media dell'incarico 4.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | 10.9yrs | US$525.00k | 0.016% HK$ 6.2m | |
| Co-Founder | 11.2yrs | US$803.00k | 0.040% HK$ 15.1m | |
| Co-Founder & Executive Director | 4.2yrs | US$645.00k | Nessun dato | |
| Chief Strategy Officer & Executive Director | 5.7yrs | US$595.00k | 0.049% HK$ 18.7m | |
| Independent Non-executive Director | 1.8yrs | US$70.00k | 0.00030% HK$ 114.2k | |
| Member of Advisory Board | 2.5yrs | Nessun dato | Nessun dato | |
| Member of Advisory Board | 6.8yrs | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 1.8yrs | US$100.00k | Nessun dato | |
| Member of Scientific Advisory Board | 2.3yrs | Nessun dato | Nessun dato | |
| Independent Non-Executive Director | 7.7yrs | US$100.00k | 0.00068% HK$ 258.9k | |
| Independent Non-Executive Director | 2.3yrs | US$100.00k | Nessun dato | |
| Independent Non-Executive Director | 2.3yrs | US$100.00k | Nessun dato |
3.3yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1548 sono considerati esperti (durata media dell'incarico 3.3 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/29 16:54 |
| Prezzo dell'azione a fine giornata | 2026/07/29 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Genscript Biotech Corporation è coperta da 12 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |